Information Provided By: 
Fly News Breaks for July 17, 2019
MNK
Jul 17, 2019 | 05:45 EDT
Barclays analyst Balaji Prasad maintains an Equal Weight rating on Mallinckrodt with an $11 price target after the company permanently discontinued its Phase 2b study of Acthar in patients with amyotrophic lateral sclerosis. The trial result raises some uncertainty over increased Acthar utilization that may have followed positive clinical readouts, Prasad tells investors in a research note. Further, he believes the halted study "further clouds" the Acthar growth outlook.
News For MNK From the Last 2 Days
There are no results for your query MNK
